logo
  

Aldeyra Reports Positive Top-line Results From Phase 3 INVIGORATE Trial - Quick Facts

Aldeyra Therapeutics, Inc. (ALDX) reported positive top-line results from the phase 3 INVIGORATE clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in patients with allergic conjunctivitis. The company said the clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints.

Aldeyra plans to meet with the FDA in the second half of 2021 to discuss the INVIGORATE results and the potential submission of a New Drug Application.

Shares of Aldeyra Therapeutics were up 25% in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration approved Boehringer Ingelheim Pharmaceuticals, Inc.'s Pradaxa (dabigatran etexilate) oral blood thinning medication for children. Pradaxa is the first FDA-approved blood thinning medication that children can take by mouth. The only other approved blood thinning medication for children is given by injection. Amazon.com Inc.'s two-day Prime Day event is happening now with more than 2 million deals on offer. The e-commerce giant's biggest shopping extravaganza of the year started June 21 at 3 a.m. EDT and runs for 48 hours, through June 22. Prime Day 2021 will feature the largest number of deals ever offered in the seven year history of the Prime Day Celebrations. New deals are being launched throughout The European Commission announced Tuesday that it has opened a formal antitrust investigation to assess whether Google has violated EU competition rules by favoring its own online display advertising technology services in the so called "ad tech" supply chain, to the detriment of competing providers...
RELATED NEWS
Follow RTT